Observational study finds lower dopamine markers in long COVID patients linked to symptoms — Evidence Review
Published in eBioMedicine, by researchers from Centre for Addiction and Mental Health, University Health Network
Researched by
— the AI search engine for science
Table of Contents
A new study suggests that damage to dopamine-releasing neurons in the brain may underlie many symptoms of long COVID, providing biological evidence for persistent fatigue, cognitive problems, and loss of motivation. Related research broadly supports this finding, indicating that SARS-CoV-2 can affect dopamine pathways and contribute to neurological and neuropsychiatric symptoms (Centre for Addiction and Mental Health).
- Multiple prior studies have found that COVID-19 can cause neuroinflammation and alter dopamine metabolism, potentially leading to symptoms similar to those seen in neurodegenerative conditions such as Parkinson’s disease 2 4 6.
- Experimental models and in vitro studies show that SARS-CoV-2 can directly infect and damage dopaminergic neurons, and persistent viral presence in the brain is associated with behavioral and cognitive changes 3 5 6.
- Neuroimaging and molecular imaging studies have previously detected changes in brain structure, blood flow, and neurotransmitter function in COVID-19 survivors, but this new study provides the strongest direct evidence to date linking dopamine neuron injury with long COVID symptoms 7 8 10.
Study Overview and Key Findings
The persistent neurological symptoms experienced by many long COVID patients—including fatigue, memory impairment, and reduced motivation—have lacked a clear biological explanation. This new study addresses that gap by using advanced imaging to directly assess dopamine neuron integrity in affected individuals. By employing positron emission tomography (PET) scans, the research team identified a reduction in dopamine neuron markers in specific brain regions, correlating these changes with patient-reported symptoms. This approach goes beyond prior work by linking measurable brain changes to clinical outcomes, offering a potential target for therapeutic intervention.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Centre for Addiction and Mental Health, University Health Network |
| Journal Name | eBioMedicine |
| Authors | Yuhan Karida Liu, Devina Persaud, Erica L. Vieira, Joeffre Braga, Pablo Rusjan, Laura Miler, Jennifer S. Rabin, Tina McCluskey, Isabelle Boileau, Thomas Chao, Michael Bagby, Lucas Narciso, Lauren Rose Gray, Neil Vasdev, Kimberly Desmond, Stefan Kloiber, Jerry Warsh, Muhammad Ishrat Husain, Kelly Smart, Wei Wang, Jeffrey H. Meyer |
| Population | People with long COVID |
| Methods | Observational Study |
| Outcome | Dopamine neuron integrity and related symptoms |
| Results | Lower dopamine markers in long COVID patients linked to symptoms. |
Literature Review: Related Studies
To situate these findings within the broader context of current research, we searched the Consensus database, which includes over 200 million research papers. The following search queries were used to identify relevant studies:
- long COVID dopamine neurons damage
- dopamine markers long COVID symptoms
- brain scans long COVID neurological effects
Summary Table of Related Study Topics and Findings
| Topic | Key Findings |
|---|---|
| How does SARS-CoV-2 impact dopamine neurons and neurotransmission? | - SARS-CoV-2 infection can directly reduce dopamine production and cause loss of dopaminergic neurons in experimental models and organoids 5 6. - Chronic inflammation and infection may disrupt genes involved in dopamine synthesis and metabolism, indirectly affecting brain function 1 2 6. |
| What neuroimaging and neuropathological changes are observed in long COVID? | - COVID-19 is associated with changes in brain structure, including reduced grey matter and altered white matter microstructure, as well as regional hypometabolism and limbic system involvement 7 8 9 10. - Some imaging findings resemble those seen in neurodegenerative diseases like Parkinson’s 10. |
| What are the neurological and psychiatric symptoms of long COVID, and their mechanisms? | - Long COVID patients frequently experience fatigue, memory impairment, depression, and anxiety, with more severe symptoms in those initially hospitalized 3 11. - Persistent viral presence and neuroinflammation in the brainstem are linked to neurodegenerative and neuropsychiatric symptoms 3 4. |
| Are dopamine-related mechanisms implicated in post-COVID parkinsonism or neurodegeneration? | - SARS-CoV-2 can exacerbate Parkinson’s disease progression via microglia-neuron crosstalk and dopamine neuron loss, suggesting shared pathways with long COVID neurological sequelae 2 4. - Some cases of parkinsonism post-COVID show loss of nigrostriatal integrity, but causality and long-term risk remain unclear 2 10. |
How does SARS-CoV-2 impact dopamine neurons and neurotransmission?
Multiple studies indicate that SARS-CoV-2 can disrupt dopamine-related pathways both directly and indirectly. Experimental infection of human midbrain organoids and iPSC-derived dopaminergic neurons leads to reduced dopamine production, loss of dopaminergic neurons, and altered expression of key enzymes in dopamine biosynthesis. Additionally, chronic inflammation and changes in gut-brain axis gene expression may further disturb dopamine metabolism, potentially explaining persistent neurological symptoms.
- SARS-CoV-2 reduces dopamine production and leads to loss of dopamine neurons in in vitro and organoid models 5 6.
- Infected enterocytes co-regulate genes involved in dopamine metabolism, suggesting a gut-brain pathway for chronic neurological effects 1.
- These changes may contribute to neuropsychiatric symptoms commonly seen in long COVID, such as fatigue and cognitive impairment 2 6.
- The new study adds in vivo human evidence to these experimental findings by linking dopamine neuron injury to clinical symptoms.
What neuroimaging and neuropathological changes are observed in long COVID?
Neuroimaging studies of COVID-19 survivors consistently reveal structural and functional brain changes, including cortical thinning, altered cerebral blood flow, and white matter abnormalities. Some of these changes are most pronounced in limbic and fronto-temporal regions and are associated with cognitive decline. PET and SPECT studies have observed variable but sometimes extensive hypometabolism, particularly in regions connected to olfaction and memory.
- Imaging studies report grey and white matter changes, reduced global brain size, and regional hypometabolism 7 8 9 10.
- Some neuroimaging abnormalities are reversible, while others may persist or resemble those seen in degenerative disorders 8 10.
- The new study extends these findings by focusing on the dopamine system and providing molecular imaging evidence for dopamine neuron loss.
- This approach helps clarify which neuroimaging abnormalities are directly tied to clinical symptoms in long COVID.
What are the neurological and psychiatric symptoms of long COVID, and their mechanisms?
Long COVID is associated with a broad spectrum of neurological and psychiatric symptoms, including fatigue, memory and attention deficits, depression, anxiety, and sleep disturbances. Persistent viral RNA in the brain and ongoing neuroinflammation are implicated in these symptoms, as seen in animal models and human studies. Severity can vary, with hospitalized individuals often experiencing worse outcomes.
- Long COVID patients often report cognitive deficits, mood disorders, and persistent fatigue, with objective impairments detected in neuropsychological testing 3 11.
- Animal models show persistent viral presence in the brainstem leading to neurodegenerative and neuropsychiatric symptoms 3.
- Neuroinflammation appears to play a key role, particularly in brain regions rich in dopamine neurons 2 3 4.
- The new study supports a mechanistic link between dopamine neuron injury and specific symptoms such as motivation loss and memory difficulties.
Are dopamine-related mechanisms implicated in post-COVID parkinsonism or neurodegeneration?
Emerging evidence suggests that SARS-CoV-2 may influence the risk of Parkinson’s disease-like symptoms by targeting dopamine neurons and promoting neuroinflammatory processes. Some post-COVID cases of parkinsonism have been reported, and experimental studies demonstrate that viral components can accelerate neurodegeneration in susceptible models. However, the long-term risk and prevalence of Parkinson’s disease following COVID-19 remain uncertain.
- SARS-CoV-2 spike protein can exacerbate neurodegeneration in Parkinson’s disease models via microglial activation and loss of dopamine neurons 4.
- Clinical and imaging studies have identified post-COVID parkinsonism, with some patients showing nigrostriatal dopamine deficits 2 10.
- The relationship between COVID-19, dopamine dysfunction, and increased risk of neurodegenerative disease remains under investigation 2 4.
- The new study strengthens the case for dopamine system involvement but does not establish causality for Parkinson’s disease.
Future Research Questions
While this new evidence for dopamine neuron injury in long COVID marks a significant advance, critical questions remain. Further research is needed to clarify causal pathways, identify at-risk populations, and determine whether targeted dopamine therapies can alleviate symptoms. Long-term studies will be essential to assess the risk of neurodegenerative diseases and to develop evidence-based interventions.
| Research Question | Relevance |
|---|---|
| Does dopamine-targeted therapy improve long COVID neurological symptoms? | Determining whether medications that enhance dopamine signaling can alleviate fatigue, memory problems, and motivation loss is critical for developing effective treatments 2 4 6. |
| What is the long-term risk of Parkinson's disease following COVID-19? | Some evidence links SARS-CoV-2 infection with parkinsonism and dopaminergic neuron loss, but the long-term risk and mechanisms remain unclear 2 4 10. |
| How does neuroinflammation contribute to dopamine neuron injury in long COVID? | The relationship between persistent brain inflammation and dopamine neuron loss needs clarification to identify potential therapeutic targets 2 3 9. |
| Are there biomarkers that predict which COVID-19 patients develop dopaminergic brain injury? | Identifying clinical or molecular markers for vulnerability to dopamine neuron injury could inform patient monitoring and early intervention 8 11. |
| Can dopamine neuron injury in long COVID be reversed or prevented over time? | Understanding the potential for recovery or prevention of dopamine neuron injury is important for prognosis and rehabilitation strategies 7 10. |